Show simple item record

dc.contributor.authorOrtiz, Justin R.
dc.contributor.authorHickling, Julian
dc.contributor.authorNeuzil, Kathleen M.
dc.creatorOrtiz, J.
dc.date.accessioned2019-07-01T18:41:11Z
dc.date.available2019-07-01T18:41:11Z
dc.date.issued2018-02-08
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037040388&origin=inward
dc.identifier.urihttp://hdl.handle.net/10713/9845
dc.description.abstractIn August 2016, the World Health Organization (WHO) convened the “Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses” to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting. © 2017 World Health Organization.en_US
dc.description.sponsorshipThe authors acknowledge the contributions of the Centers for Disease Control and Prevention ( CK14-1402 ), which provides financial support to the World Health Organization Initiative for Vaccine Research. The authors also acknowledge contributions of the US National Institutes of Health ( U01AI108543-01 ), which provided grant funding for partial support of this meeting.en_US
dc.description.urihttps://www.doi.org/10.1016/j.vaccine.2017.11.061
dc.language.isoen_USen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofVaccineen_US
dc.subjectInfluenzaen_US
dc.subjectNextgeneration influenza vaccineen_US
dc.subjectPandemic influenza vaccineen_US
dc.subjectSeasonal influenza vaccineen_US
dc.subjectUniversal influenza vaccineen_US
dc.subjectVaccine developmenten_US
dc.titleReport on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23–24 August 2016en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.vaccine.2017.11.061
dc.identifier.pmid29221895
dc.relation.volume36


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record